☰

Byron D. Johnson - Publications

Affiliations: 
Microbiology, Molecular Genetics, and Immunology Medical College of Wisconsin, Milwaukee, WI, United States 
Area:
Microbiology Biology, Genetics, Immunology, Oncology
Tree Info Similar researchers PubMed Report error

37 high-probability publications. We are testing a new system for linking publications to authors. You can help! If you notice any inaccuracies, please sign in and mark papers as correct or incorrect matches. If you identify any major omissions or other inaccuracies in the publication list, please let us know.

Year Citation  Score
2020 Shah NN, Jerkins JH, Johnson BD, Hari P. Treatment-Emergent Tumor Lysis Syndrome With PI3Kδ-γ Inhibition After CAR T-Cell Therapy for Chronic Lymphocytic Leukemia. Jco Oncology Practice. OP2000022. PMID 32603254 DOI: 10.1200/OP.20.00022  0.344
2019 Jing W, Chen J, Cai Y, Chen Y, Schroeder JA, Johnson BD, Cui W, Shi Q. Induction of activated T follicular helper cells is critical for anti-FVIII inhibitor development in hemophilia A mice. Blood Advances. 3: 3099-3110. PMID 31648333 DOI: 10.1182/bloodadvances.2019000650  0.317
2018 Wesley EM, Xin G, McAllister D, Malarkannan S, Newman DK, Dwinell MB, Cui W, Johnson BD, Riese MJ. Diacylglycerol kinase ζ (DGKζ) and Casitas b-lineage proto-oncogene b-deficient mice have similar functional outcomes in T cells but DGKζ-deficient mice have increased T cell activation and tumor clearance. Immunohorizons. 2: 107-118. PMID 30027154 DOI: 10.4049/immunohorizons.1700055  0.312
2018 Tsai S, McOlash L, Palen K, Johnson B, Duris C, Yang Q, Dwinell MB, Hunt B, Evans DB, Gershan J, James MA. Development of primary human pancreatic cancer organoids, matched stromal and immune cells and 3D tumor microenvironment models. Bmc Cancer. 18: 335. PMID 29587663 DOI: 10.1186/s12885-018-4238-4  0.33
2017 Jing W, Gershan JA, Holzhauer S, Weber J, Palen K, McOlash L, Pulakanti K, Wesley E, Rao S, Johnson BD, Riese MJ. T cells deficient in diacylglycerol kinase-ζ are resistant to PD-1 inhibition and help create persistent host immunity to leukemia. Cancer Research. PMID 28916658 DOI: 10.1158/0008-5472.Can-17-1309  0.336
2017 Jing W, Gershan JA, Blitzer GC, Palen K, Weber J, McOlash L, Riese M, Johnson BD. Adoptive cell therapy using PD-1(+) myeloma-reactive T cells eliminates established myeloma in mice. Journal For Immunotherapy of Cancer. 5: 51. PMID 28642819 DOI: 10.1186/S40425-017-0256-Z  0.309
2017 Xin G, Schauder DM, Jing W, Jiang A, Joshi NS, Johnson B, Cui W. Pathogen boosted adoptive cell transfer immunotherapy to treat solid tumors. Proceedings of the National Academy of Sciences of the United States of America. PMID 28069963 DOI: 10.1073/pnas.1614315114  0.456
2016 Palen K, Weber J, Dwinell MB, Johnson BD, Ramchandran R, Gershan JA. E-cadherin re-expression shows in vivo evidence for mesenchymal to epithelial transition in clonal metastatic breast tumor cells. Oncotarget. PMID 27270319 DOI: 10.18632/oncotarget.9715  0.328
2016 Palen KA, Jing W, Weber JJ, Tilkens SB, Chan AM, Johnson BD, Gershan JA. Erratum to: Separation and Characterization of Epithelial and Mesenchymal-like Murine Mammary Tumor Cells Reveals Epithelial Cell Differentiation Plasticity and Enhanced Tumorigenicity of Epithelial-enriched Tumor Cells. Cancer Microenvironment : Official Journal of the International Cancer Microenvironment Society. PMID 26747049 DOI: 10.1007/s12307-015-0179-5  0.361
2015 Gershan JA, Barr KM, Weber JJ, Jing W, Johnson BD. Immune modulating effects of cyclophosphamide and treatment with tumor lysate/CpG synergize to eliminate murine neuroblastoma. Journal For Immunotherapy of Cancer. 3: 24. PMID 26082836 DOI: 10.1186/S40425-015-0071-3  0.685
2015 Barr KM, Gershan JA, Johnson BD. Hematopoietic stem cell transplantation and lymphodepletion for the treatment of cancer Cancer Immunology: Bench to Bedside Immunotherapy of Cancers. 189-201. DOI: 10.1007/978-3-662-44946-2_10  0.629
2013 Barr KM, Jing W, Hallett WH, Gershan JA, Johnson BD. Examining T cells at vaccine sites of tumor-bearing hosts provides insights to dysfunctional T-cell immunity. Journal of Immunotherapy (Hagerstown, Md. : 1997). 36: 41-51. PMID 23211619 DOI: 10.1097/Cji.0B013E318274590E  0.675
2013 Palen KA, Jing W, Weber JJ, Tilkens SB, Chan AM, Johnson BD, Gershan JA. Separation and Characterization of Epithelial and Mesenchymal-like Murine Mammary Tumor Cells Reveals Epithelial Cell Differentiation Plasticity and Enhanced Tumorigenicity of Epithelial-enriched Tumor Cells. Cancer Microenvironment : Official Journal of the International Cancer Microenvironment Society. 6: 79-89. PMID 22237886 DOI: 10.1007/s12307-011-0095-2  0.416
2013 Gershan J, Barr K, Weber J, Johnson B. Cyclophosphamide in combination with tumor lysate and TLR9 ligand regresses murine neuroblastoma Journal For Immunotherapy of Cancer. 1. DOI: 10.1186/2051-1426-1-S1-P74  0.692
2011 Jing W, Yan X, Hallett WH, Gershan JA, Johnson BD. Depletion of CD25⁺ T cells from hematopoietic stem cell grafts increases posttransplantation vaccine-induced immunity to neuroblastoma. Blood. 117: 6952-62. PMID 21521781 DOI: 10.1182/blood-2010-12-326108  0.455
2010 Kohler ME, Johnson BD, Palen K, Chen QR, Khan J, Orentas RJ. Tumor antigen analysis in neuroblastoma by serological interrogation of bioinformatic data. Cancer Science. 101: 2316-24. PMID 20718755 DOI: 10.1111/J.1349-7006.2010.01694.X  0.345
2010 Kohler ME, Hallett WH, Chen QR, Khan J, Johnson BD, Orentas RJ. Early expression of stem cell-associated genes within the CD8 compartment after treatment with a tumor vaccine. Cellular Immunology. 265: 65-73. PMID 20692654 DOI: 10.1016/J.Cellimm.2010.07.004  0.472
2009 Jing W, Gershan JA, Johnson BD. Depletion of CD4 T cells enhances immunotherapy for neuroblastoma after syngeneic HSCT but compromises development of antitumor immune memory. Blood. 113: 4449-57. PMID 19182203 DOI: 10.1182/blood-2008-11-190827  0.45
2009 Jing W, Johnson B. Depletion of CD4 T Cells Leads to Increased Tumor Immunity After HSCT Immunotherapy but Results In Loss of Memory Biology of Blood and Marrow Transplantation. 15: 83-84. DOI: 10.1016/j.bbmt.2008.12.259  0.364
2008 Yan X, Johnson BD, Orentas RJ. Induction of a VLA-2 (CD49b)-expressing effector T cell population by a cell-based neuroblastoma vaccine expressing CD137L. Journal of Immunology (Baltimore, Md. : 1950). 181: 4621-31. PMID 18802064 DOI: 10.4049/Jimmunol.181.7.4621  0.304
2008 Zhou Q, Yan X, Gershan J, Orentas RJ, Johnson BD. Expression of macrophage migration inhibitory factor by neuroblastoma leads to the inhibition of antitumor T cell reactivity in vivo. Journal of Immunology (Baltimore, Md. : 1950). 181: 1877-86. PMID 18641325 DOI: 10.4049/Jimmunol.181.3.1877  0.47
2007 Zhou Q, Johnson BD, Orentas RJ. Cellular immune response to an engineered cell-based tumor vaccine at the vaccination site. Cellular Immunology. 245: 91-102. PMID 17543914 DOI: 10.1016/J.Cellimm.2007.04.004  0.32
2007 Johnson BD, Jing W, Orentas RJ. CD25+ regulatory T cell inhibition enhances vaccine-induced immunity to neuroblastoma. Journal of Immunotherapy (Hagerstown, Md. : 1997). 30: 203-14. PMID 17471167 DOI: 10.1097/01.Cji.0000211336.91513.Dd  0.35
2007 Zheng J, Kohler ME, Chen Q, Weber J, Khan J, Johnson BD, Orentas RJ. Serum from mice immunized in the context of Treg inhibition identifies DEK as a neuroblastoma tumor antigen. Bmc Immunology. 8: 4. PMID 17397536 DOI: 10.1186/1471-2172-8-4  0.405
2007 Jing W, Orentas RJ, Johnson BD. Induction of immunity to neuroblastoma early after syngeneic hematopoietic stem cell transplantation using a novel mouse tumor vaccine. Biology of Blood and Marrow Transplantation : Journal of the American Society For Blood and Marrow Transplantation. 13: 277-92. PMID 17317581 DOI: 10.1016/J.Bbmt.2006.11.018  0.464
2007 Orentas R, Hodge JW, Johnson BD. Cancer Vaccines and Tumor Immunity Cancer Vaccines and Tumor Immunity. 1-334. DOI: 10.1002/9780470170113  0.355
2006 Yan X, Orentas RJ, Johnson BD. Tumor-derived macrophage migration inhibitory factor (MIF) inhibits T lymphocyte activation. Cytokine. 33: 188-98. PMID 16522371 DOI: 10.1016/J.Cyto.2006.01.006  0.315
2006 Orentas RJ, Kohler ME, Johnson BD. Suppression of anti-cancer immunity by regulatory T cells: back to the future. Seminars in Cancer Biology. 16: 137-49. PMID 16376101 DOI: 10.1016/J.Semcancer.2005.11.007  0.343
2006 Jing W, Orentas RJ, Johnson BD. Vaccine-Induced Anti-Neuroblastoma Immunity Early after HSCT Arises in the Presence of Foxp3+CD25+CD4+ T Cells. Blood. 108: 3692-3692. DOI: 10.1182/Blood.V108.11.3692.3692  0.344
2006 Jing W, Yan X, Orentas R, Johnson B. Syngeneic neuroblastoma cells transiently-transfected with plasmid DNA vectors encoding a panel of immune stimulatory molecules can induce anti-tumor immunity early after BMT Biology of Blood and Marrow Transplantation. 12: 93. DOI: 10.1016/J.Bbmt.2005.11.286  0.339
2005 Johnson BD, Gershan JA, Natalia N, Zujewski H, Weber JJ, Yan X, Orentas RJ. Neuroblastoma cells transiently transfected to simultaneously express the co-stimulatory molecules CD54, CD80, CD86, and CD137L generate antitumor immunity in mice. Journal of Immunotherapy (Hagerstown, Md. : 1997). 28: 449-60. PMID 16113601 DOI: 10.1097/01.Cji.0000171313.93299.74  0.338
2005 Jing W, Orentas RJ, Johnson BD. Induction of Tumor Immunity Early after Syngeneic Bone Marrow Transplantation (BMT) by Transient Transfection of Mouse Neuroblastoma with Plasmid DNA Vectors Encoding a Panel of Immune Stimulatory Molecules. Blood. 106: 1308-1308. DOI: 10.1182/Blood.V106.11.1308.1308  0.497
2004 Orentas R, Yan X, Natalia N, Johnson B. Tumor-Derived Macrophage Migration Inhibitory Factor (MIF) Inhibits Effective Immune Activation Journal of Immunotherapy. 27: S47. DOI: 10.1097/00002371-200411000-00171  0.307
2004 Johnson B, Gershan J, Natalia N, Zujewski H, Weber J, Yan X, Orentas R. Nucleofection of Mouse Neuroblastoma Cells with Plasmid DNA Vectors Can Be Used To Generate Novel Cell-Based Tumor Vaccines Journal of Immunotherapy. 27: S24. DOI: 10.1097/00002371-200411000-00087  0.33
2002 Bin Q, Johnson BD, Schauer DW, Casper JT, Orentas RJ. Production of macrophage migration inhibitory factor by human and murine neuroblastoma. Tumour Biology : the Journal of the International Society For Oncodevelopmental Biology and Medicine. 23: 123-9. PMID 12218292 DOI: 10.1159/000064028  0.372
2002 Orentas RJ, Schauer D, Bin Q, Johnson BD. Electrofusion of a weakly immunogenic neuroblastoma with dendritic cells produces a tumor vaccine. Cellular Immunology. 213: 4-13. PMID 11747351 DOI: 10.1006/Cimm.2001.1864  0.436
1998 Johnson BD, Hanke CA, Becker EE, Truitt RL. Sca1(+)/Mac1(+) nitric oxide-producing cells in the spleens of recipients early following bone marrow transplant suppress T cell responses in vitro. Cellular Immunology. 189: 149-59. PMID 9790729 DOI: 10.1006/Cimm.1998.1373  0.306
Show low-probability matches.